Menü
Microsoft selbst warnt vor der Verwendung von Internet Explorer, da er nicht mehr den neuesten Web- und Sicherheitsstandards entspricht. Wir können daher nicht garantieren, dass die Seite im Internet Explorer in vollem Umfang funktioniert. Nutze bitte Chrome oder Firefox.

QIAGEN N.V. to release results for Q1 2023 and hold webcast


Venlo, The Netherlands, April 18, 2023 (GLOBE NEWSWIRE) -- QIAGEN N.V. (NYSE: QGEN) (Frankfurt Stock Exchange: QIA) announced its plans to release results for the first quarter 2023.

Press release date / time: Wednesday, May 3, shortly after 22:05 Frankfurt time / 21:05 London time / 16:05 New York time.

Conference call date / time: Thursday, May 4, at 15:00 Frankfurt time / 14:00 London time / 09:00 New York time.

Three options for joining the conference call

  1. Register for call back connection - Click here: Connect me

Service available 15 minutes before call start 

  1. Dial-in by phone

U.S.: +1 929 477 0402
UK: +44 (0)330 165 3655
GER: +49 (0)69 6610 2490
Conference ID: 5702254
To avoid waiting time, please join the event conference 5-10 minutes prior to the start time. 

  1. Access the audio webcast - Click here: Access Webcast

A conference call replay will be available by using the following link:
https://globalmeet.webcasts.com/starthere.jsp?ei=1596346&tp_key=edbc0e49e6

Contact: [email protected]

About QIAGEN

QIAGEN N.V., a Netherlands-based holding company, is the leading global provider of Sample to Insight solutions that enable customers to gain valuable molecular insights from samples containing the building blocks of life. Our sample technologies isolate and process DNA, RNA and proteins from blood, tissue and other materials. Assay technologies make these biomolecules visible and ready for analysis. Bioinformatics software and knowledge bases interpret data to report relevant, actionable insights. Automation solutions tie these together in seamless and cost-effective workflows. QIAGEN provides solutions to more than 500,000 customers around the world in Molecular Diagnostics (human healthcare), Applied Testing (primarily forensics), Pharma (pharma and biotech companies) and Academia (life sciences research). As of December 31, 2022, QIAGEN employed approximately 6,200 people in over 35 locations worldwide. Further information can be found at http://www.qiagen.com.

CONTACT: John Gilardi 
QIAGEN N.V.
+49 2103 29 11711
ir@QIAGEN.com

Phoebe Loh
QIAGEN N.V.
+49 2103 29 11457
ir@QIAGEN.com


Quelle Hugin

QIAGEN NV Aktie

40,47 €
-0,15 %
Die QIAGEN NV Aktie notiert heute etwas tiefer, mit einem Rückgang von -0,15 %.
Eine Reihe von Buy-Einschätzungen für QIAGEN NV, keine Sell-Einschätzungen in Sicht.
Das von der Community festgelegte Kursziel von 47 € für QIAGEN NV deutet auf ein leichtes Wachstumspotenzial im Vergleich zu 40.47 € hin.
Like: 0
Teilen
GlobeNewswire is one of the world's largest newswire distribution networks, specializing in the delivery of corporate press releases financial disclosures and multimedia content to the media, investment community, individual investors and the general public.

Rechtlicher Hinweis

Kommentare